How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
Summary
- Since August 1, 2026 a new generic in Korea is priced at 45% of the original's pre-entry price instead of 53.55%, falling to 36% or 29% if it misses the bioequivalence or registered-substance requirement, and stepped pricing now starts after 13 same-formulation listings. 1 2
- The cut changed behaviour at once: in October 2026 only 18 calculation-based drugs were listed, 75% below this year's monthly average, and some firms moved to new formulations that escape the stepped cut. 3
- Modified drugs are expected to keep their edge: they are priced at 70%, or 77% for a new dosage or regimen, so the gap to plain generics widened, but the drug ministry says simple salt changes have never qualified for modified-drug status. 4 5
- The price review is largely arithmetic against the ministry's rules on the company's own documents; reasonable filings pass quietly, expensive ones get scrutiny. 6 7
- National listing is only the first gate: each hospital's drug committee decides separately, trial hospitals are the natural first wins, and clinic-heavy rep forces carry the volume. 8 9 10
- The fund is large and still growing, with KRW 28.2653 trillion of drug claims in 2025, which is why pricing policy keeps leaning towards cheaper drugs. 11 12
Transcript
01The new 45% rate, and what it did in its first months
You sat on the pricing side for years and now advise companies. What should a foreign drug maker understand first about listing a generic in Korea this year?
That the arithmetic changed on 1 August, and it changed more than most people outside Korea noticed. Until then a generic was priced off the original's price before generic entry and ended up at 53.55% of it. The new base is 45%. 13 1 And that 45% is the top. Miss one of the requirements and you drop to 36%, miss both and you are at 29%. 1 The requirements are the ones we have had since July 2020: run your own bioequivalence study, and use a registered drug substance. 2
Then there is the queue. Stepped pricing used to start after the 20th listing of the same formulation. Now it starts after 13. 13 1 In Korea a successful molecule gets crowded fast, so for many molecules you are already past that line before you file. 3 14
Has it actually changed what companies file?
Immediately. Look at the October list. Only 18 calculation-based drugs were listed, against 8 new drugs, and the calculation-based count was 75% below this year's monthly average. 3 The 45% rate took effect on 1 August, and October is when its effect showed up in the listings. 1 3
The other part is that companies now think twice. A generic that would have been worth listing at the old rate is not always worth it at 45%, once you add the bioequivalence study, the dossier and the reps. And the newly listed generics came in 21-33% below the equivalents already on the list, so the newcomer is also the cheapest one on the shelf. 3 1 I tell clients: the price is no longer the negotiation, it is the starting condition. 6
02How a listing really moves
Walk me through it. A company has its marketing approval for a generic. What happens next?
For a generic, or anything priced by formula, there is not much drama. The company files the price application with the review agency, people in Korea just say Shim-pyeong-won, and the reviewer checks the product against the pricing principles. Which original, which formulation, which requirements met, how many same products already listed. It is mostly arithmetic on the documents you submit. 6
When I was inside, the honest truth was that we did not have the people to re-check every number a company sent. We applied the ministry's rules to the papers in front of us. So the quality of the dossier matters more than outsiders think. A missing certificate for the drug substance is not a debate, it is a lower price. 6 2
And what makes an official look harder at a file?
Price. A filing that asks for a reasonable price usually goes through without a second look. The expensive ones are the ones we read twice. 7 That has not changed in all my years, because the pressure on the insurance fund only goes one way, towards the cheaper drug. 12
New drugs are a different road, with an evaluation committee and a price negotiation with the insurer. The reform adds an expedited pathway meant to finish listing within 100 days for the drugs it covers. 13 But for a generic or a modified drug, the question is not speed. It is which box your product falls into, because the box sets the price. 6
03Generics under the new rule
Is there any way for a generic to avoid the stepped cut?
The legal way is to be a different product. In October some companies listed orally disintegrating tablets of pitavastatin, a cholesterol molecule. They were classed as a new formulation and listed at 471 won for 2 mg and 707 won for 4 mg, the same for all 3 companies. As an ordinary tablet they would have fallen into the stepped cut, because 13 or more equivalents already exist. 3
You will see more of that, dispersible tablets, new strengths, combinations. Some of it is real value for patients and some of it is mostly a price strategy, and a reviewer can feel the difference even when the rule cannot. 6 7
What does a late entrant face now?
Under the tiered system before the reform, the 21st and later identical products were listed at 85% of the lowest existing price or 38.69%, whichever is lower. 2 With the threshold moved to 13, that floor arrives much sooner. 13 For a foreign company with a contract manufacturer and no strong rep force, being a late entrant at the lowest price on the list is not a business, it is a listing. 10
And remember the penalty for missing a requirement went up from 15% to 20% per requirement. 2 So I always ask two things before anything else: did you run your own bioequivalence study, and is your drug substance registered. If the answer is no, do the sums again. 2 6
04Modified drugs: where the margin went
Where did the margin go, then?
Into modified drugs, what we call gae-ryang sinyak, incrementally modified drugs. They are priced at 70%, as a premium on top of the 53.55% base, and at 77% when there is a new dosage or regimen. The reform was expected to keep that 70% rate, so with generics at 45% the gap between a plain generic and a modified drug got wider. 4
Combinations are the big example. A modified combination is priced on the sum of the single ingredients' prices before patent expiry, at 68% for innovative companies and 59.5% for general companies, reportedly moving to 60%. 4 That is why every local company has a cholesterol or blood-pressure combination. In 2024 the top ingredient by insurer spending was the ezetimibe plus rosuvastatin combination, at KRW 704.6 billion. 15
Can a company just change the salt of a famous molecule and call it modified?
Not any more, if it ever really could. The drug ministry's draft guideline says salt or isomer changes must produce clinically meaningful results, and the ministry said simple salt changes have never qualified. 5 The salt-form copies of a blockbuster that local firms used to launch after patent expiry were priced as their own products, but they did not carry modified-drug status. 5 14
The draft also opens the door to evidence beyond pharmacokinetics, like development history and why those ingredients in those amounts. But one thing did not change: if two companies co-develop and one manufactures for the other, the consignor still does not get modified-drug status even when the consignee does. Under the 2022 revision that meant one side got a 10% price premium and the other did not. 5 Foreign licensors should read that clause before signing a partnership. 5 16
How long does the premium last?
It is not forever. Today it is 1 year with extensions of 2 years at a time on review, and it was expected to become 1 year plus another 3 years if you meet the domestic production criteria, continuing while no later generic is listed. 4 So a foreign company that imports finished product should not assume it keeps the full premium as long as a local producer would. 4
05After the list: hospitals, doctors and reps
Once a product is listed nationally, is the job done?
That is the mistake I see most from foreign teams. The national list only says the insurer will pay. Each hospital has its own drug committee, the yaksa wiwonhoe, and it decides separately whether your product goes on its formulary. Price matters there too. 8 People call getting in the door 'landing'. A big hospital may land only a handful of products per molecule. 8
The companies that know this plan it from the clinical study. The hospitals that run your trial tend to become your first formulary wins, and afterwards the reps use the hospital's name when they visit other doctors. 9 For a modified version of a leading molecule, the doctors want local clinical data and they watch what the formulary decides. 17
And outside the big hospitals?
Clinics are where the volume is for many chronic drugs, and the clinic market belongs to the firms with large, well-trained rep forces and low prices. The established names go to general and university hospitals and lean on their image. A firm without hospital coverage finds a partner who has it. 10 A firm new to a therapy area uses something it already sells to the same doctors as the door-opener, then promotes the new product next to it. 18
On promotion, the room has narrowed. Companies have had to record the economic benefits they give doctors and pharmacists since 2018, things like samples, conference support and product briefings, and the review agency launched a system to publish those reports, with the 2024 reports due to go out through it for the first time. 19 After warnings over illegal support, firms shifted towards clinical data. 20 I would not build a launch plan on anything you would not want published. 19 20
06The fund, the originators and the re-evaluations
Why is the government pushing so hard on generic prices now?
Because the bill keeps growing. Drug claims were KRW 28.2653 trillion in 2025, up 4.7%, and drugs were 23.7% of total insurance medical spending. 11 Generics were 44.4% of drug expenditure in 2024, up from 40.9%. 15 When generics are 44.4% of the spend, generic prices are where the savings are. 15 12
The list is also getting shorter. There were 21,770 covered products in January 2026, down from 25,047 in January 2022. 11 Officials do not say it this way, but fewer, cheaper copies per molecule is the direction. 12
What happens to the originator when generics arrive?
The originator gets 70% for the first year after the generic is listed, and up to 4 years at about 60% if it meets domestic production requirements or has 3 or fewer companies listed. 21 People worried that a generic with a premium could end up priced above the original. The review agency told the National Assembly that under the system design that is unlikely, because both prices are calculated from the original's ceiling before adjustment. 21
In practice the originator's defence is older than any rule. Many local copies arrive within months, the fight turns to price, and the originator answers with outcome data, a new strength or indication, and a selective price cut where it hurts most. 14 Local firms also tend to expect the first entrant to take most of the growth, so the second and third wait and watch before fixing price and date. 22
What about re-evaluation of drugs already listed?
That got harder. From 2026 a re-evaluation ends in one of a few ways: coverage maintained, delisted, or moved to selective benefit with a 50% or 80% co-payment. The option to keep coverage by accepting a lower price is gone. 13 For a company, that means you cannot buy your way out of a weak evidence file any more. 13 12
07Advice to a newcomer, and what worries me
A Japanese or Chinese company wants to bring a generic or a modified drug to Korea. What should it do?
Decide which box you are in before you decide anything else. A plain generic at 45%, behind 13 or more listed copies, is a hard business. 1 A modified drug at 70%, or a combination priced on the ingredients' old prices, can be a real one, but only if the ministry recognises it and you control the dossier yourself. 4 5
Then plan hospitals at the same time as the listing. Choose trial sites you want as customers, budget for the drug committees, and if you have no rep force, find the partner before launch, not after. 9 8 10 And be careful with the sales targets you hear from local partners. Announced targets are often more press release than plan. 23 Companies hire people like me because we know how the reviewers read a file. That helps with the paper, not with the doctors. 16
What would change your view, and what worries you?
If the drop in listings in October turns out to be a short dip, then the market is just repricing and life goes on. 3 If it stays low for a year, the fewer, cheaper copies the policy wanted will come with fewer suppliers too, and that is a different problem. 3 12
What worries me is supply. The review agency says it does not separately track supply stoppages linked to price cuts. 21 When a low-price product stops making money, the company does not argue, it quietly stops producing. The policy is built to save money on the arithmetic, and the arithmetic does not see the factory. 12
Sources and basis
- 1The Ministry of Health and Welfare issued the revised drug decision and adjustment standards on July 30, 2026, after an administrative notice period from May 13 to July 13, 2026; the 45% generic calculation rate (previously 53.55%) takes effect on August 1; the price applied to a generic that misses a requirement moves from 85% to 80%, giving 36% or 29% depending on how many requirements are met; stepped pricing for same-formulation listings now starts after 13 items instead of 20; preferential rates are 60% for innovative pharmaceutical companies and 50% for quasi-innovative and supply-stabilising companiesPublic source · Dailypharm, 31 Jul 2026 · link
- 2Since July 2020, generics must meet 2 conditions for the highest price: conducting their own bioequivalence (BE) study and using a registered drug substance (DMF); each unmet requirement lowers the ceiling, and the penalty rises from 15% to 20% under the reform; under tiered pricing, the 21st and later entries with an identical formulation are listed at 85% of the lowest existing price or 38.69%, whichever is lower; the industry had proposed a base of 48.20% instead of 45%Public source · Dailypharm (English edition), 30 Mar 2026 · link
- 3In October 2026, 18 calculation-based drugs and 8 new drugs were listed for reimbursement; calculation-based listings were 75% below this year's average monthly count; newly listed generics came in 21-33% below existing equivalent products; pitavastatin orally disintegrating tablets from 3 companies were classed as a new formulation and listed at 471 won (2 mg) and 707 won (4 mg), the same for all 3, whereas listing as a regular tablet would have triggered the stepped cut because 13 or more equivalents already exist; Dong-A ST listed a pitavastatin/ezetimibe combination at 734 won, 21.0% below the lowest equivalentPublic source · Dailypharm, 12 Oct 2026 · link
- 4Incrementally modified drugs are priced at 70%, a premium on top of the 53.55% base, and those with a new dosage or regimen at 77%; incrementally modified combination drugs are priced on the sum of the single ingredients' pre-patent-expiry prices, at 68% for innovative companies and 59.5% for general companies, reportedly changing to 60%; the 70% premium rate was expected to be maintained under the reform; the premium period, currently 1 year with extensions of 2 years at a time on review, was expected to become 1 year plus an additional 3 years if domestic production criteria are met, continuing while no subsequent generic is listed; with the generic rate falling to 45% the price gap between generics and incrementally modified drugs widensPublic source · Dailypharm, 6 May 2026 · link
- 5The Ministry of Food and Drug Safety drafted the 4th revision of its incrementally modified drug recognition guideline, the first since 2022, collecting opinions until the end of October 2026; the draft accepts evidence other than pharmacokinetic results, such as development history and the rationale for ingredients and amounts; salt or isomer changes must produce clinically meaningful results, and the ministry said simple salt changes have never qualified; a consignor's product is still not recognised even if the consignee's product qualifies; under the 2022 revision, consignees in one co-development case received recognition and a 10% price premium while consignors were excludedPublic source · Dailypharm, 22 Oct 2026 · link
- 6A price application for a generic or modified drug is checked against the ministry's pricing principles using the documents the company submits; reviewers have limited capacity to verify company data independentlyKIRA field interviews · KIRA field interviews, Seoul
- 7A filing that asks for a reasonable price usually goes through without a second review; officials look hard at the expensive onesKIRA field interviews · KIRA field interviews, Seoul
- 8National listing is not enough: each hospital's drug committee must add the product to its formulary separately, and price influences inclusionKIRA field interviews · KIRA field interviews, Seoul
- 9Hospitals that host a company's clinical trial tend to become its first formulary wins and first sales base, and the trial hospital's name is used by reps after launchKIRA field interviews · KIRA field interviews, Seoul
- 10Generic-led firms win in clinics with large, well-trained rep forces and low prices; established firms target general and university hospitals and lean on corporate image; firms without hospital coverage ally with a partnerKIRA field interviews · KIRA field interviews, Seoul
- 11HIRA's 2025 covered drug claims: KRW 28.2653 trillion, up 4.7% from KRW 26.9897 trillion in 2024; drugs were 23.7% of total national health insurance medical expenses of KRW 118.7809 trillion; 21,770 covered products as of January 2026, down from 25,047 in January 2022; in 2025, 948 products were added and 1,199 removed; cardiovascular drugs KRW 5.5246 trillion, 19.5% of claimsPublic source · HIRA 2025 covered drug claims report, reported by Dailypharm, 1 Jul 2026 · link
- 12Pressure on the insurance fund steadily pushes pricing officials to favour cheaper drugs and to re-evaluate the prices of off-patent originatorsKIRA field interviews · KIRA field interviews, Seoul
- 13Korea's Health Insurance Policy Deliberation Committee approved a comprehensive reform of the drug pricing system on March 26, 2026, building on a November 2025 plan; generic and patent-expired originator prices, which ultimately fell to 53.55% of the pre-generic-entry originator price, get a new base rate of 45% (the November 2025 proposal had targeted the 40s range); existing listed products step down to 45% in phases over 11 years from 2026 through 2036 rather than at once; the stepped generic price reduction now starts at the 13th generic per formulation instead of the 20th; from 2026, reimbursement re-evaluation outcomes are limited to maintaining coverage, delisting, or selective benefit with a 50% or 80% co-payment, and the option to keep coverage through a price reduction is removed; an expedited listing pathway is designed to complete listing within 100 daysPublic source · Shin & Kim, Healthcare & Life Sciences newsletter, 14 Apr 2026 · link
- 14When a blockbuster loses its patent, many local copies arrive within months and competition quickly becomes price-led; the originator defends with outcome data, new strengths or indications and selective price cutsKIRA field interviews · KIRA field interviews, Seoul
- 15NHIS 2024 reimbursed drug expenditure report: total drug expenditure KRW 27.6625 trillion, up 5.6%; original drugs KRW 15.3434 trillion, 55.6% of expenditure, down from 59.1%; generic drugs KRW 12.2591 trillion, 44.4%, up from 40.9%; the top ingredient was the ezetimibe + rosuvastatin combination at KRW 704.6 billion, up 16.3%Public source · NHIS report released 23 Mar 2026, reported by Dailypharm (English edition), 24 Mar 2026 · link
- 16Companies hire managers with past regulator experience because they are seen to help approval, listing and promotionKIRA field interviews · KIRA field interviews, Seoul
- 17Doctors' acceptance of a modified copy of a leading molecule depends on local clinical data and on the hospital formulary decisionKIRA field interviews · KIRA field interviews, Seoul
- 18Firms new to a therapy area use an existing product as a door-opener with the same doctors, then promote the new product alongside it in package dealsKIRA field interviews · KIRA field interviews, Seoul
- 19HIRA launched an Expense Report Management System to publish expense reports in which pharmaceutical companies, device companies and wholesalers record economic benefits given to healthcare professionals and pharmacists, such as samples, conference support, clinical trial support and product briefings; the reporting duty was introduced in 2018 and HIRA planned to publish the 2024 reports through the system for the first timePublic source · Asia Economy, 17 Nov 2025 · link
- 20After official warnings over illegal support to prescribers, firms cut sponsorship and leaned more on clinical data in promotionKIRA field interviews · KIRA field interviews, Seoul
- 21In a reply to a National Assembly audit question, HIRA said that under the system design a generic price is unlikely to overtake the original's price; both the calculated generic price and its premium are based on the original's pre-adjustment ceiling price; the original receives 70% for the first year after generic listing, which can extend up to 4 years at about 60% if it meets domestic production requirements or has 3 or fewer listing companies; HIRA does not separately track supply stoppages linked to price cuts; the reform took effect in August 2026Public source · Dailypharm, 4 Nov 2026 · link
- 22Local makers expect the first entrant after patent expiry to take most of the growth; later entrants watch the first launch before fixing their own price and timing, and launch dates are rarely fixed in advanceKIRA field interviews · KIRA field interviews, Seoul
- 23Publicly announced launch sales targets are often inflated as a form of advertising, and the firm's own sales staff see them as unrealisticKIRA field interviews · KIRA field interviews, Seoul